443 related articles for article (PubMed ID: 30342955)
21. Antisense oligonucleotides containing conformationally constrained 2',4'-(N-methoxy)aminomethylene and 2',4'-aminooxymethylene and 2'-O,4'-C-aminomethylene bridged nucleoside analogues show improved potency in animal models.
Prakash TP; Siwkowski A; Allerson CR; Migawa MT; Lee S; Gaus HJ; Black C; Seth PP; Swayze EE; Bhat B
J Med Chem; 2010 Feb; 53(4):1636-50. PubMed ID: 20108935
[TBL] [Abstract][Full Text] [Related]
22. Acute hepatotoxicity of 2' fluoro-modified 5-10-5 gapmer phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins.
Shen W; De Hoyos CL; Sun H; Vickers TA; Liang XH; Crooke ST
Nucleic Acids Res; 2018 Mar; 46(5):2204-2217. PubMed ID: 29390093
[TBL] [Abstract][Full Text] [Related]
23. Differential Uptake of Antisense Oligonucleotides in Mouse Hepatocytes and Macrophages Revealed by Simultaneous Two-Photon Excited Fluorescence and Coherent Raman Imaging.
Mukherjee P; Aksamitiene E; Alex A; Shi J; Bera K; Zhang C; Spillman DR; Marjanovic M; Fazio M; Seth PP; Frazier K; Hood SR; Boppart SA
Nucleic Acid Ther; 2022 Jun; 32(3):163-176. PubMed ID: 34797690
[TBL] [Abstract][Full Text] [Related]
24. Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals.
Swayze EE; Siwkowski AM; Wancewicz EV; Migawa MT; Wyrzykiewicz TK; Hung G; Monia BP; Bennett CF
Nucleic Acids Res; 2007; 35(2):687-700. PubMed ID: 17182632
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and Clinical Pharmacology Considerations of GalNAc
Wang Y; Yu RZ; Henry S; Geary RS
Expert Opin Drug Metab Toxicol; 2019 Jun; 15(6):475-485. PubMed ID: 31144994
[No Abstract] [Full Text] [Related]
26. Fatty Acid-Modified Gapmer Antisense Oligonucleotide and Serum Albumin Constructs for Pharmacokinetic Modulation.
Hvam ML; Cai Y; Dagnæs-Hansen F; Nielsen JS; Wengel J; Kjems J; Howard KA
Mol Ther; 2017 Jul; 25(7):1710-1717. PubMed ID: 28641935
[TBL] [Abstract][Full Text] [Related]
27. Evaluating the Knockdown Activity of MALAT1 ENA Gapmers In Vitro.
Iwashita S; Shoji T; Koizumi M
Methods Mol Biol; 2020; 2176():155-161. PubMed ID: 32865789
[TBL] [Abstract][Full Text] [Related]
28. Delivery of GalNAc-Conjugated Splice-Switching ASOs to Non-hepatic Cells through Ectopic Expression of Asialoglycoprotein Receptor.
Scharner J; Qi S; Rigo F; Bennett CF; Krainer AR
Mol Ther Nucleic Acids; 2019 Jun; 16():313-325. PubMed ID: 30965276
[TBL] [Abstract][Full Text] [Related]
29. Development of gapmer antisense oligonucleotide with deoxyribonucleic guanidine (DNG) modifications.
Kojima N; Shrestha AR; Akisawa T; Piao H; Kizawa H; Ohmiya Y; Kurita R
Nucleosides Nucleotides Nucleic Acids; 2020; 39(1-3):258-269. PubMed ID: 31556356
[TBL] [Abstract][Full Text] [Related]
30. The Combination of Mesyl-Phosphoramidate Inter-Nucleotide Linkages and 2'-
Zhang L; Liang XH; De Hoyos CL; Migawa M; Nichols JG; Freestone G; Tian J; Seth PP; Crooke ST
Nucleic Acid Ther; 2022 Oct; 32(5):401-411. PubMed ID: 35861704
[TBL] [Abstract][Full Text] [Related]
31. Drug discovery and development scheme for liver-targeting bridged nucleic acid antisense oligonucleotides.
Wada F; Yamamoto T; Kobayashi T; Tachibana K; Ito KR; Hamasaki M; Kayaba Y; Terada C; Yamayoshi A; Obika S; Harada-Shiba M
Mol Ther Nucleic Acids; 2021 Dec; 26():957-969. PubMed ID: 34760338
[TBL] [Abstract][Full Text] [Related]
32. Characterization of the Activity and Distribution of a 2'-O-Methoxyethyl-Modified Antisense Oligonucleotide in Models of Acute and Chronic Kidney Disease.
Donner AJ; Bell TA; Greenlee S; Graham MJ; Crooke RM
Nucleic Acid Ther; 2018 Oct; 28(5):297-306. PubMed ID: 30133341
[TBL] [Abstract][Full Text] [Related]
33. Phospholamban Inhibition by a Single Dose of Locked Nucleic Acid Antisense Oligonucleotide Improves Cardiac Contractility in Pressure Overload-Induced Systolic Dysfunction in Mice.
Morihara H; Yamamoto T; Oiwa H; Tonegawa K; Tsuchiyama D; Kawakatsu I; Obana M; Maeda M; Mohri T; Obika S; Fujio Y; Nakayama H
J Cardiovasc Pharmacol Ther; 2017 May; 22(3):273-282. PubMed ID: 27811197
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and antisense properties of fluoro cyclohexenyl nucleic acid (F-CeNA), a nuclease stable mimic of 2'-fluoro RNA.
Seth PP; Yu J; Jazayeri A; Pallan PS; Allerson CR; Østergaard ME; Liu F; Herdewijn P; Egli M; Swayze EE
J Org Chem; 2012 Jun; 77(11):5074-85. PubMed ID: 22591005
[TBL] [Abstract][Full Text] [Related]
35. Insights from crystal structures into the opposite effects on RNA affinity caused by the S- and R-6'-methyl backbone modifications of 3'-fluoro hexitol nucleic acid.
Pallan PS; Yu J; Allerson CR; Swayze EE; Seth P; Egli M
Biochemistry; 2012 Jan; 51(1):7-9. PubMed ID: 22229409
[TBL] [Abstract][Full Text] [Related]
36. A convenient synthesis of 5'-triantennary N-acetyl-galactosamine clusters based on nitromethanetrispropionic acid.
Migawa MT; Prakash TP; Vasquez G; Wan WB; Yu J; Kinberger GA; Østergaard ME; Swayze EE; Seth PP
Bioorg Med Chem Lett; 2016 May; 26(9):2194-7. PubMed ID: 27025342
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of MDR1 gene expression by chimeric HNA antisense oligonucleotides.
Kang H; Fisher MH; Xu D; Miyamoto YJ; Marchand A; Van Aerschot A; Herdewijn P; Juliano RL
Nucleic Acids Res; 2004; 32(14):4411-9. PubMed ID: 15316104
[TBL] [Abstract][Full Text] [Related]
38. Safety and Tolerability of GalNAc
Baker BF; Xia S; Partridge W; Engelhardt JA; Tsimikas S; Crooke ST; Bhanot S; Geary RS
Nucleic Acid Ther; 2024 Feb; 34(1):18-25. PubMed ID: 38227794
[TBL] [Abstract][Full Text] [Related]
39. Enhancing antisense efficacy with multimers and multi-targeting oligonucleotides (MTOs) using cleavable linkers.
Subramanian RR; Wysk MA; Ogilvie KM; Bhat A; Kuang B; Rockel TD; Weber M; Uhlmann E; Krieg AM
Nucleic Acids Res; 2015 Oct; 43(19):9123-32. PubMed ID: 26446989
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides.
Wada S; Yasuhara H; Wada F; Sawamura M; Waki R; Yamamoto T; Harada-Shiba M; Obika S
J Control Release; 2016 Mar; 226():57-65. PubMed ID: 26855051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
